Cover Image
市場調查報告書

掌腱膜攣縮症:開發中產品分析

Dupuytren Contracture - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 484629
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
掌腱膜攣縮症:開發中產品分析 Dupuytren Contracture - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 31 Pages
簡介

掌腱膜攣縮症(Dupuytren′s Contracture)是一種侵犯掌腱膜,並延伸至手指筋膜,最終導致掌指及指間關節攣縮的緩慢進行性發展的疾病。它會在手掌皮膚下面形成局部的瘢痕組織。瘢痕積聚在通常覆蓋拉扯手指抓握的肌腱組織中。隨著掌腱膜攣縮症惡化,更多的膜變厚和縮短。皮膚在該區域最終會燮成皮膚窪陷發生皺紋。掌腱膜攣縮症的進展速度從輕微皮膚皺褶多年到手指的快速攣縮(固定彎曲位置)而有所不同。受到它的影響手指可能錯位到完全無法伸直 。因此還可能導致喪失正常抓握力。掌腱膜攣縮症少有疼痛,除非受影響的手指被無意的過度伸展。掌腱膜攣縮症纖維增生性障礙。該疾病會導致手指攣縮,並可能導致顯著的畸形和殘疾。造成這種疾病的因素包括種族,遺傳傾向,性別和年齡。風險因素(環境)包括飲酒,吸煙,創傷,癲癇和糖尿病。如果手指以十分大的角度扭曲,在治療後一般會接受讓手指可伸直的手術。

本報告提供全球各國治療掌腱膜攣縮症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

掌腱膜攣縮症;概要

掌腱膜攣縮症 - 治療藥的開發

  • 開發中產品 概要
  • 開發中產品:各企業
  • 開發中產品:各大學/研究機關
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • MediWound Ltd

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9694IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dupuytren Contracture - Pipeline Review, H2 2017, provides an overview of the Dupuytren Contracture (Musculoskeletal Disorders) pipeline landscape.

Dupuytren contracture is a hand deformity that usually develops slowly, over decades. Dupuytren contracture affects the connective tissue under the skin of the palm. It is a localized formation of scar tissue beneath the skin of the palm of the hand. The scarring accumulates in a tissue that normally covers the tendons that pull the fingers to grip. As Dupuytren contracture progresses, more of the fascia becomes thickened and shortened. Dimpling and puckering of the skin over the area eventually occurs. Dupuytren contracture varies in its rate of progression from minor skin puckering for many years to rapid contracture (fixed flexed position) of fingers. Dupuytren contracture can lead to an inability to fully extend the affected finger from the flexed position. This can result in a loss of normal grasping. Dupuytren contracture is seldom associated with much, if any, pain unless the affected fingers are inadvertently forcefully hyperextended. Dupuytren contracture is a fibroproliferative disorder. It involves the tissue beneath the palm of the hand that leads to finger contracture and may result in significant deformity and disability. Factors contributing to the disease include ethnicity, genetic predisposition, sex and age. Risk factors (environmental) include alcohol consumption, smoking, trauma, epilepsy and diabetes. Dupuytren contracture is usually treated by an operation to straighten the fingers followed by therapy if the angle that the fingers are bent at is large enough. Surgical treatment requires extensive postoperative therapy and there are chances that symptoms often re-occur. The molecular pathophysiology of Dupuytren contracture is complex. Extensive exploration of the molecular basis of Dupuytren contracture has led to the development of new treatment modalities such as by Clostridium histolyticum collagenase injection. There still remains a long way in the development of more promising therapies for Dupuytren contracture.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dupuytren Contracture - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dupuytren Contracture (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dupuytren Contracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dupuytren Contracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Dupuytren Contracture (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dupuytren Contracture (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Dupuytren Contracture (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dupuytren Contracture (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dupuytren Contracture (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dupuytren Contracture (Musculoskeletal Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dupuytren Contracture (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dupuytren Contracture (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dupuytren Contracture - Overview
    • Dupuytren Contracture - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Dupuytren Contracture - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Dupuytren Contracture - Companies Involved in Therapeutics Development
    • MediWound Ltd
    • Pacira Pharmaceuticals Inc
  • Dupuytren Contracture - Drug Profiles
    • Biologic to Inhibit TNF Alpha for Dupuytrens Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bupivacaine ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit TNF-Alpha for Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MWPC-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Peyronies Disease, Dupuytren Contracture and Pancreatic Islet Transplant Rejection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Dupuytren Contracture - Dormant Projects
  • Dupuytren Contracture - Product Development Milestones
    • Featured News & Press Releases
      • Dec 20, 2016: MediWound Granted U.S. Patent for MWPC003 for the Treatment of Connective Tissue Diseases
      • May 31, 2016: Data Published in Bone & Joint Research Supports MediWound's Bromelain-Based Enzyme for the Release of Dupuytren's Contracture
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Dupuytren Contracture, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Dupuytren Contracture - Pipeline by MediWound Ltd, H2 2017
  • Dupuytren Contracture - Pipeline by Pacira Pharmaceuticals Inc, H2 2017
  • Dupuytren Contracture - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Dupuytren Contracture, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top